Anthony Y. Sun M.D.
Net Worth
Last updated:
What is Anthony Y. Sun M.D. net worth?
The estimated net worth of Dr. Anthony Y. Sun M.D. is at least $39,053,076 as of 5 Apr 2022. He owns shares worth $1,869,187 as insider, has earned $32,397,489 from insider trading and has received compensation worth at least $4,786,400 in Zentalis Pharmaceuticals, Inc..
What is the salary of Anthony Y. Sun M.D.?
Dr. Anthony Y. Sun M.D. salary is $957,280 per year as Pres, Chief Executive Officer & Executive Chairman in Zentalis Pharmaceuticals, Inc..
How old is Anthony Y. Sun M.D.?
Dr. Anthony Y. Sun M.D. is 53 years old, born in 1972.
What stocks does Anthony Y. Sun M.D. currently own?
As insider, Dr. Anthony Y. Sun M.D. owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Zentalis Pharmaceuticals, Inc. (ZNTL) | Pres, Chief Executive Officer & Executive Chairman | 1,175,589 | $1.59 | $1,869,187 |
What does Zentalis Pharmaceuticals, Inc. do?
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; Phase 1/2 clinical trial for the treatment of advanced solid tumors as a monotherapy and in an ongoing Phase 1b clinical trial in combination with chemotherapy in patients with platinum resistant ovarian cancer; and Phase 2 monotherapy trial for a tumor agnostic, predictive biomarker. The company's other lead product candidate includes ZN-c5, an oral selective estrogen receptor degrader that is in a Phase 1/2 clinical trial for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or advanced or metastatic breast cancer. In addition, it is involved in developing ZN-d5, a selective inhibitor of B-cell lymphoma 2 that is in a Phase 1 clinical trial for the treatment of non-Hodgkin's lymphoma and acute myelogenous leukemia; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor, which is in Phase 1/2 clinical trial for the treatment of advanced non-small cell lung cancer. Further, the company is developing BCL-xL heterobifunctional degraders based on E3 ligases not expressed in platelets, allowing for the avoidance of dose-limiting thrombocytopenia associated with BCL-xL inhibitors. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Mayo Foundation for Medical Education and Research; SciClone Pharmaceuticals International (Cayman) Development Ltd.; Pfizer, Inc.; Eli Lilly and Company; GlaxoSmithKline, and Zentera Therapeutics (Cayman), Ltd. The company was incorporated in 2014 and is based in New York, New York.
Anthony Y. Sun M.D. insider trading
Zentalis Pharmaceuticals, Inc.
Dr. Anthony Y. Sun M.D. has made 53 insider trades between 2020-2022, according to the Form 4 filled with the SEC. Most recently he sold 2,500 units of ZNTL stock worth $130,273 on 5 Apr 2022.
The largest trade he's ever made was exercising 64,562 units of ZNTL stock on 5 Apr 2021. As of 5 Apr 2022 he still owns at least 1,175,589 units of ZNTL stock.
Zentalis Pharmaceuticals key executives
Zentalis Pharmaceuticals, Inc. executives and other stock owners filed with the SEC:
- Dr. Anthony Y. Sun M.D. (53) Pres, Chief Executive Officer & Executive Chairman
- Dr. Kevin D. Bunker Ph.D. (52) Chief Operating Officer
- Mr. Cam S. Gallagher M.B.A. (55) Sec. & Director
- Ms. Alexis M. Pinto J.D. (58) Chief Legal Officer & Sec.